中国骨质疏松杂志

抗疏强骨合剂结合基础抗骨质疏松药物治疗原发性骨质疏松症的疗效分析

Efficacy of anti-osteoporosis and bone strengthening agent combined with basic anti-osteoporosis drugs on primary osteoporosis

DOI：10.3969/j.issn.1006-7108.2020.01.016

中文关键词: 抗疏强骨合剂原发性骨质疏松症骨密度骨转换指标临床观察

英文关键词:Anti-osteoporosis and bone strengthening mixture primary osteoporosis bone mineral density bone turnover index clinical observation

基金项目:国家自然科学基金(81473711)；国家中管局科研专项(JDZX2015280)；陕西省自然科学计划项目(2018JM7132)；陕西省教育厅计划项目(18JK0226)；咸阳市课题项目(2017K02-76)；陕西省重点科技创新团队项目(2013KJT-26)；陕西省三秦学者创新团队支持计划；刘德玉名老中医药专家传承工作室项目；关中李氏骨伤流派传承工作室项目

作者	单位
姚洁1 欧国峰2 董博3* 杨锋3 袁普卫3 王国柱2 肖斌2 康武林3 刘芳1 李晓伟1	1.陕西中医药大学，陕西咸阳 712046 2.陕西中医药大学第二附属医院，陕西咸阳 712000 3.陕西中医药大学附属医院，陕西咸阳 712000

摘要点击次数: 743

全文下载次数: 545

中文摘要:

目的观察抗疏强骨合剂结合基础抗骨质疏松药物对原发性骨质疏松症的临床有效性及安全性，探讨其应用前景。方法 174例原发性骨质疏松症患者随机分为治疗组和对照1组、对照2组，每组各58例。治疗组给予抗疏强骨合剂、碳酸钙D3片、阿仑膦酸钠片治疗，对照1组单纯给予碳酸钙D3片、阿仑膦酸钠片治疗，对照2组给予仙灵骨葆胶囊、碳酸钙D3片、阿仑膦酸钠片治疗，连续服用6个月后观察并分析各组治疗前后中医证候积分、骨密度值、骨代谢生化指标改善情况。结果（1）治疗组在中医证候疗效评价中总有效率为87.18%，优于对照1组（66.67%）（P＜0.05），与对照2组（82.05%）比较无明显差异（P＞0.05）；在主证单项症状和次症状单项症状改善情况中，治疗组明显优于对照1组和对照2组（P＜0.05）。（2）3种治疗方法均能改善患者腰椎及股骨颈部位的骨密度，但治疗组的效果更佳，更能提高患者的骨密度，与对照1组和对照2组比较差异有统计学意义（P＜0.05）。（3）治疗组能改善患者骨转换指标，治疗前后比较差异有统计学意义（P＜0.05）。结论抗疏强骨合剂结合基础抗骨质疏松药物治疗原发性骨质疏松症疗效确切，能改善患者中医证候积分，增加患者骨密度，促进骨形成，降低骨吸收，改善骨代谢，起到防治骨质疏松症的作用。

英文摘要:

Objective To observe the clinical efficacy and safety of anti-osteoporosis and bone strengthening mixture combined with basic anti-osteoporosis drugs in primary osteoporosis, and to explore its application prospects. Methods A total of 174 patients with primary osteoporosis were randomly divided into treatment group, control group 1, and control group 2, with 58 cases in each group. Patients in the treatment group received anti-osteoporosis and bone strengthening mixture, calcium carbonate D3 tablets, and alendronate sodium tablets. Patients in the control group 1 received calcium carbonate D3 tablets and alendronate sodium tablets. Patients in the control group 2 received Xianlinggubao capsules, calcium carbonate D3 tablets, and alendronate sodium tablets. After 6 months of continuous observation, the changes of TCM syndrome scores, bone mineral density, and bone metabolic and biochemical indicators before and after the treatment were analyzed. Results (1) The total effective rate of the treatment group in the evaluation of TCM syndromes was 87.18%, which was better than that of the control group (66.67%, P<0.05), and there was no significant difference compared with the control group 2 (82.05%, P>0.05). In the improvement of single symptom and sub-symptoms, the treatment group was significantly better than the control group 1 and the control group 2 (P<0.05). (2) All the three treatment methods improved bone mineral density of the lumbar spine and the femoral neck. The treatment group had better effect in improving the bone mineral density of the patients. Compared with the control group 1 and the control group 2, there was significant difference (P<0.05). (3) The treatment group improved the bone turnover index of the patients, and there was significant difference before and after treatment (P<0.05). Conclusion Anti-osteoporosis and bone strengthening mixture is effective in the treatment of primary osteoporosis. It improves TCM syndrome scores, increases bone mineral density, promotes bone formation, reduces bone resorption, improves bone metabolism, and prevents osteoporosis.

查看全文查看/发表评论下载PDF阅读器

关闭